← feed

Is NCT02732184 results overdue?

Yes — results are overdue. Primary completion was 2017-11-01; the FDAAA-801 reporting deadline (2018-11-01) passed 2880 days ago and no results are posted on ClinicalTrials.gov.

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

NCT IDNCT02732184 ↗
SponsorImmedica Pharma AB (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-11-01 (ACTUAL)
Reporting deadline2018-11-01 (completion + 365d)
Days overdue2880
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 104b568bd41c2c5b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02732184. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →